Multifactorial resistance to aminopeptidase inhibitor prodrug CHR2863 in myeloid leukemia cells: down-regulation of carboxylesterase 1, drug sequestration in lipid droplets and pro-survival activation ERK/Akt/mTOR

Aminopeptidase inhibitors are receiving attention as combination chemotherapeutic agents for the treatment of refractory acute myeloid leukemia. However, the factors determining therapeutic efficacy remain elusive. Here we identified the molecular basis of acquired resistance to CHR2863, an orally a...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Oncotarget
Päätekijät: Verbrugge, Sue Ellen, Al, Marjon, Assaraf, Yehuda G., Kammerer, Sarah, Chandrupatla, Durga M.S.H., Honeywell, Richard, Musters, Rene P.J., Giovannetti, Elisa, O'Toole, Tom, Scheffer, George L., Krige, David, de Gruijl, Tanja D., Niessen, Hans W.M., Lems, Willem F., Kramer, Pieternella A., Scheper, Rik J., Cloos, Jacqueline, Ossenkoppele, Gert J., Peters, Godefridus J., Jansen, Gerrit
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Impact Journals LLC 2015
Aiheet:
Research Paper
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4868683/
https://ncbi.nlm.nih.gov/pubmed/26496029
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.6169
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia